医中誌リンクサービス


文献リスト

1)Nishikawa K, Nashimoto A, Miki A, et al. Result of HER2 status in Japanese metastatic gastric cancer: Prospective cohort study (JFMC44-1101).J Clin Oncol. 2013 (suppl 4; abstr 10); 31
医中誌リンクサービス
2)A Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin as First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer (NCT01364493). http://www.clinicaltrials.gov/ct2/show/NCT01364493
医中誌リンクサービス
3)Efficacy and Safety of Trastuzumab, Capecitabine y Oxaliplatine as Treatment Gastric Cancer Metastatic (HER2)Positive (HerXO) (NCT01503983). http://www.clinicaltrials.gov/ct2/show/NCT01503983
医中誌リンクサービス
4)Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC) (Her+XELOX) (NCT01396707). http://www.clinicaltrials.gov/ct2/show/NCT01396707
医中誌リンクサービス
5)Ding X, Qu X, Fan Y, et al. Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells. Anticancer Drugs. 2014; 25: 315-22
PubMed CrossRef
医中誌リンクサービス
6)von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol. 2009; 27: 1999-2006
PubMed CrossRef
医中誌リンクサービス
7)Komatsu Y. Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed (UMIN000007636)
医中誌リンクサービス
8)Makiyama A. Randomized phase II study comparing trastuzumab beyond progression in combination with weekly paclitaxel vs. weekly paclitaxel alone after failure of a trastuzumab, fluoro- pyrimidine and platinum containing chemo-therapy for patients with HER2-positive advanced gastric or gastro-esophageal junction cancer (UMIN000009297)
医中誌リンクサービス
9)Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach (HerFLOT) (NCT01472029). http://www.clinicaltrials.gov/ct2/show/NCT01472029
医中誌リンクサービス
10)A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer (NCT01130337). http://www.clinicaltrials.gov/ct2/show/NCT01130337
医中誌リンクサービス
11)A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study) (NCT01748773). http://www.clinicaltrials.gov/ct2/show/NCT01748773
医中誌リンクサービス
12)Satoh T, Xu RH, Chung HC, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014; 32: 2039-49
PubMed CrossRef
医中誌リンクサービス
13)Randolph Hecht J, Bang Y-J, Qin S, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial. J Clin Oncol. 2013 (suppl; abstr LBA4001); 31
医中誌リンクサービス
14)Oh D-Y, Lee K-W, Cho JY, et al. A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen. J Clin Oncol. 2012 (suppl 4; abstr 54); 30
医中誌リンクサービス
15)A Phase I-II Study of HM781-36B(Poziotinib)Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer (NCT01746771). http://www.clinicaltrials.gov/ct2/show/NCT01746771
医中誌リンクサービス
16)Janjigian YY, Ilson D, Kelsen DP, et al. A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer. J Clin Oncol. 2012 (suppl; abstr TPS4144); 30
医中誌リンクサービス
17)A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer (NCT01641939). http://www.clinicaltrials.gov/ct2/show/NCT01641939
医中誌リンクサービス
18)Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013; 14: 461-71
PubMed CrossRef
医中誌リンクサービス
19)A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (JACOB試験) (NCT01774786). http://www.clinicaltrials.gov/ct2/show/NCT01774786
医中誌リンクサービス
20)Kang YK, Rha SY, Tassone P, et al. A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer. Br J Cancer. 2014; 111: 660-6
PubMed CrossRef
医中誌リンクサービス


NPO医学中央雑誌刊行会
https://www.jamas.or.jp/
info@jamas.or.jp